TWiV reveals a prediction of the expected endemic seasonality of COVID-19, based on circulation of human coronaviruses, and ecological clearance of vaccine-targeted human papillomaviruses and an increase in circulation of non-targeted virus types.
In his weekly clinical update, Dr. Griffin discusses stress in America 2023, CDC expanding testing of international air traveler samples to include flu, RSV, and other respiratory viruses, missed opportunities for preventing congenital syphilis, intrinsic and effective severity of COVID-19 cases infected with the ancestral strain and omicron BA.2 variant in Hong Kong, T-cell immunity against severe acute respiratory syndrome coronavirus 2 measured by an interferon-γ release assay is strongly associated with patient outcomes in vaccinated persons hospitalized with delta or omicron variants, masks during pandemics caused by respiratory pathogens, behavioral factors and SARS-CoV-2 transmission heterogeneity within a household cohort in Costa Rica, convalescent plasma for Covid-19–induced ARDS in mechanically ventilated patients, and olfactory and gustatory function 3 years after mild COVID-19.
On this episode of TWiV we discuss unusual properties of monoclonal antibodies: one that that binds the receptor attachment site and blocks infection with all three poliovirus serotypes, and others that inhibit Ebolavirus spread from cell to cell.
In his weekly clinical update, Dr. Griffin discusses health worker–perceived working conditions and symptoms of poor mental health, Mpox neutralizing antibodies at 6 months from mpox infection or MVA-BN vaccination, newborn and early infant outcomes…
Klaus Früh visits the Incubator to discuss his career and his work on cytomegalovirus-vectored vaccines which are unique in their ability to persistently maintain an immune shield of effector memory T cells, including highly unconventional MHC-II and MHC-E restricted CD8+ T cells.
In his weekly clinical update, Dr. Griffin discusses health worker–perceived working conditions and symptoms of poor mental health, Mpox neutralizing antibodies at 6 months from mpox infection or MVA-BN vaccination, newborn and early infant outcomes following maternal COVID-19 vaccination during pregnancy, duration of SARS-CoV-2 culturable virus shedding in children, prescribing outcomes in outpatients treated with nirmatrelvir–ritonavir for COVID-19 in an interdisciplinary community clinic, Nirmatrelvir and molnupiravir and post-COVID-19 condition in older patients, optimal duration of systemic corticosteroids in COVID-19 treatment, association between Guillain-Barré syndrome and COVID-19 infection and vaccination, SARS-CoV-2 infection correlates with male benign prostatic hyperplasia deterioration, Transplanting candidates with COVID-19, and favorable experience of transplant strategy including liver grafts from COVID-19 donors.
Vincent travels to the University of Vermont to speak with Jason, Emily, Jessica, and Dimitry about their careers and their work on SARS-CoV-2, hantaviruses, poliovirus, influenza virus, and the involvement of viruses in the autoimmune disease multiple sclerosis.
In his weekly clinical update, Dr. Griffin discusses high Influenza incidence and disease severity among children and adolescents aged <18 years, neurologic effects of SARS-CoV-2 transmitted among dogs, effectiveness of monovalent mRNA vaccines against Omicron XBB infection in Singaporean children younger than 5 years, the effectiveness of COVID-19 vaccine in the prevention of post-COVID conditions, incidence and impact of acute pericarditis in hospitalized patients with COVID‐19, serotonin reduction in post-acute sequelae of viral infection, prevalence and risk factors for long COVID and post-COVID-19 condition in Africa, safety profile and clinical and virological outcomes of nirmatrelvir-ritonavir treatment in patients with advanced chronic kidney disease and COVID-19, antiviral efficacy of molnupiravir vs ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19.
From the Centers for Excellence in Influenza Research and Response meeting in Baltimore, Vincent speaks with Ron Fouchier, Rafael Medina, and Louse Moncla about recent changes in the epidemiology of avian H5N1 influenza virus and the threat to humans and other animals.
In his weekly clinical update, Dr. Griffin discusses disease severity of RSV compared with COVID-19 and Influenza among hospitalized adults aged ≥60 years, antiviral efficacy of Molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19, Nirmatrelvir-Ritonavir and COVID-19 mortality and hospitalization among patients with vulnerability to covid-19 complications, antibiotic use among hospitalized patients with COVID-19 in the United States, one week of oral Camostat vs Placebo in nonhospitalized adults with mild-to-moderate COVID-19, assessment of the available therapeutic approaches for severe COVID-19, optimal duration of systemic Corticosteroids in COVID-19 treatment, effect of monovalent COVID-19 vaccines on viral interference between SARS-CoV-2 and several DNA viruses in patients with long-COVID syndrome, local budesonide therapy in the management of persistent hyposmia in suspected non-severe COVID-19 patients, and the safety profile and clinical and virological outcomes of Nirmatrelvir-Ritonavir treatment in patients with advanced chronic Kidney disease and COVID-19.
The Hosts of TWiV
Vincent Racaniello, Ph.D.
Rich Condit, Ph.D.
Dickson D.
Despommier, Ph.D.
Alan Dove, Ph.D.
Daniel Griffin, M.D.,
Ph.D., CTropMed CTH
Angela Mingarelli, DVM
Jolene Ramsey, Ph.D.